Abstract: A simple kinetic spectrophotometric method has been developed for the determination of lansoprazole in pharmaceutical formulations. The method is based on the oxidation of the drug with alkaline potassium permanganate at room temperature. The reaction was followed spectrophotometrically by measuring the increase in the absorbance owing to the formation of MnO 4 2-at 610 nm (Method A) and the decrease in the absorbance at 530 nm due to the disapperance of MnO 4 -(Method B). Calibration procedures were adopted for the assay of the drug. The calibration curves were linear over the concentration ranges of 5 -150 and 5 -70 mg ml -1 , with the corresponding calibration Equations: rate = -3.915´10 -6 + 5.271´10 -5 c and DA = 1.04´10 -3 + 1.78´10 -3 c for methods A, and B, respectively. A statistical comparison of the results of the proposed procedures with those of the reference spectrophotometric method show excellent agreement and indicated no significant difference between the compared methods in terms of accuracy and precision. Interval hypothesis tests were also performed, which indicated that the true bias of all samples was less than ± 2 %.
INTRODUCTION
Lansoprazole is an important proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the gastric H + , K + ATPase enzyme system at the secretory surface of the gastric parietal cells. 1 As defined in Martindale, The Extra Pharmacopeia, 2 The drug is effectively useful in the treatment of duodenal ulcer, gastric ulcer, reflux oesophagitis and helicobactor pylori infection. In addition to its efficacy in healing or maintenance treatment, it may provide a more effective system relief than other comparative agents. Owing to the vital importance of the drug, the development of a sensitive, simple and fast method for its determination is of urgent need.
The assay of drug is only listed in the monograph of The United States Pharmacopoeia, which describes a high performance liquid chromatographic method. 3 Lansoprazole has been determined in pharmaceutical preparations using high performance liquid chromatography, [4] [5] [6] high performance thin layer chromatography, 7, 8 capillary electrophoresis, 9 flow injection analysis 10 and electroanalytical methods. 11, 12 The spectrophotometric methods are the instrumental method of choice and have practical and significant advantages over other methods. In the literature, few spectrophotometric methods have been reported 13, 14 for the quantification of the cited drug. Moustafa reported 15 three spectrophotometric methods. The first two methods are based on the charge transfer complexation reaction of the drug with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and iodine. The third method involves the formation of a ternary complex of the drug with eosin and Cu(II), which absorbs maximally at 549 nm. Lansoprazole forms an ion-pair complex with bromocresol green 16 which was extracted into an orgnic solvent for quantitative determination at 420 nm. Spectrophotometric procedures for its determination in commercial dosage forms have also been discussed. They are based on the reaction of the drug with p-dimethylaminobenzaldehyde, 17 folin-ciocaltaeu's phenol reagent, 18 and vanilin. 19 The literature is still lacking a kinetic spectrophotometric method for the determination of the cited drug. Furthermore, some specific advantages in the application of a kinetic method are to be expected, such as selectivty due to the measurement of the evolution of the absorbance with the reaction time.
In this paper, a kinetically based spectrophotometric method is proposed for the determination of lansoprazole in bulk and capsules by measuring the change in the absorbance at 610 nm and 530 nm, whereby the oxidation of the drug with alkaline KMnO 4 at 25 ± 1°C is followed.
EXPERIMENTAL

Apparatus
A Shimadzu UV-visible spectrophotometer (Model No. 1601, Kyoto, Tokyo, Japan) with matched quartz cells was used to measure the absorption spectra and a Spectronic 20 D + (Milton Roy Company, USA) for recording the absorbance of the solution.
Reagents
All employed reagents were of analytical or pharmaceutical grade. The potassium permanganate (GR Grade, Merck Limited, Mumbai, India) solution, (6.0´10 -3 M) should be freshly prepared and its apparent purity was assayed titrimetrically (Vogel 2002). Sodium hydroxide (E. Merck, India) solution (1.0 M) was prepared in distilled water.
Test solution
The lansoprazole (Cipla, India, Ltd.) solution (0.1% w/v) was prepared by dissolving 100 mg of the reagent in 0.5 ml of 0.10 M NaOH and then diluting to 100 ml with distilled water. The lansoprazole solution was freshly prepared and used within 5 hours.
Marketed products
The commercial pharmaceutical preparations of lansoprazole, i.e., Lanzol (Cipla Ltd., Mumbai, India), Lansofast (Cadila Healthcare Ltd., Ahemdabad, India), Propilan (Glenmark Pharma-ceuticals Ltd., Mumbai, India) and Lancid (Brown and Burk Pharmaceuticals Ltd., Bangalore, India) were purchased from a local pharmacist.
Recommended procedure
Method A. Aliquots of 0.1 % lansoprazole solution to obtain find concentrations in the range 5-150 mg ml -1 were pipetted into a series of 10 ml volumetric flaks. Subsequently, 1.5 ml of 1 M NaOH was added followed by 2.0 ml of 6.0´10 -3 M potassium permanganate solution and then diluted to volume with distilled water. The contents of the flask were mixed well and immediately transferred to the spectrophotometric cell. The absorance at 610 nm was recorded at 25 ± 1°C as a function of time against prepared reagent blank. The initial rate of formation of MnO 4 2-at the different concentrations of lansoprazole was evaluated from the slope of the tangent to the absorbance-time curve. The calibration curve was constructed by plotting initial rate of reaction against the final concentration of lansoprazole in mg ml -1 . The amount of lansoprazole in unknown samples was calculated either from the calibration curve of the corresponding regression equation.
Method B. Aliquots of 0.1 % lansoprazole solution, corresponding to 50-700 mg, were transferred into a series of 10 mL volumetric flasks. Then 1 ml of 1 M NaOH was added, followed by 0.8 ml of 6.0 x 10 -3 M potassium permanganate solution and the solution was made up to the mark with distilled water. The decrease in the absorbance of the solution was measured at 530 nm as a function of time. The initial rate of disappearance of MnO 4 -was determined from the slope of the tangent to the absorbance-time curve. The calibration curve was constructed by plotting DA vs. lansoprazole concentration. The amount of lansoprazole in unknown samples was calculated either from the calibration graph of the corresponding regression equation.
Procedure for the determination of lansoprazole in capsules
The content of the capsules (enteric coated granules) was accurately weighed and finely powdered. An amount of the powder equivalent to 200 mg of lansoprazole was dissolved in 50 ml of methanol and allowed to stand for a few minutes before being filtered through Whatmann No. 42 filter paper. The filtrate was evaporated to dryness and the residue was dissolved in 0.5 ml of 0.1 M NaOH and diluted to25 ml with distilled water. The recovery of lansoprazole was calculated from the corresponding linear regression equations or calibration graphs.
RESULTS AND DISCUSSION
The absorption spectrum of lansoprazole solution in distilled water shows two absorption bands, peaking at 197 and 287.5 nm ( Fig. 1 curve a) while that of potassium permanganate solution in alkaline medium exhibits and absorption band peaking at 530 nm (Fig. 1curve b) . The course of the reaction commences on addition of aqueous alkaline potasium permanganate to the lansoprazole solution resulting in the formation of a new band peaking at 610 nm ( Fig. 1 curve c) . This band is attributed to the formation of manganate ions in the presence of the drug. Thus, the intensity of the green coloured solution increased with time owing to the formation of MnO 4 2-, whereas the absorbance of the solution at 530 nm decreased as the reaction proceded due to the disappearance of MnO 4 -. These facts were used to develop a kinetically based spectrophotometric method for the determination of lansoprazole.
The optimum conditions affecting the formation of manganate ions were studied and maintained throughout the experiments.
The effect of KMnO 4 concentration on the absorbance was studied in the range 1.2´10 -4 -1.44´10 -3 M (Fig. 2) , keeping all other experimental parame-ters constant, [lansoprazole] = 100.0 mg ml -1 and [NaOH] = 0.1 M. It can be seen that the highest absorbance was obtained at 9.6´10 -4 M. From this concentration up to 1.44´10 -3 M, the absorbance was unchanged. Thus, the addition of 1.21 0 -3 M KMnO 4 in the final solution proved to be sufficient for the maximum concentration of lansoprazole used in the determinations.
The dependence of NaOH concentration on the maximum absorbance was studied in the range 0.02 -0.2 M. Figure 3 shows that the absorbance increased with increasing NaOH concentration and the maximum absorbance was obtained with 0.09 M. Further increasing of the concentration of NaOH up to 0.2 M resulted in no change in absorbance. Hence, 0.15 M NaOH is recommended for the determination procedure.
In method A, under the optimized experimental conditions, the determination of lansoprazole was carried out in an excess of potassium permanganate and sodium hydroxide with respect to the initial concentration of lansoprazole. As a result, pseudo zero order reaction conditions were obtained with respect to their concentrations. Therefore, on the basis of the kinetic investigation, the kinetic equation for the oxidation of lansoprazole by KMnO 4 in alkaline medium is written as: 
where k y is the pseudo-order rate constant, c is the concentration of lansoprazole and n is the order of the reaction with respect to lansoprazole of reaction. The logarithmic form of Equation (2) may be written as: Fig. 2 . Effect of the concentration of KMnO 4 on the absorbance at 610 nm (100 mg ml -1 lansoprazole). Fig. 3 . Effect of the concentration of NaOH on the absorbance at 610 nm (100 mg ml -1 lansoprazole).
log (rate) = log k y + n log c
The initial rates of reaction were evaluated at different concentrations of lansoprazole by measuring the slopes of the initial tangent to the absorbance (at 610 nm) -time curves during the first 10 min of the reaction (Fig. 4) . The values of the results are summarized in Table I . The curve of log (rate) versus log c gave the following linear equation: log (rate) = 1.28 + 0.998 log c with a correlation coefficient (r) of 0.9998. The value of n in the equation confirmed that the reaction is first order with respect to lansoprazole with a constant of 19.1 s -1 . The calibration curve was prepared by plotting the initial rate versus the concentration of lansoprazole and was found to be linear over the concentration range of 5-10 mg ml -1 The regression analysis of the calibration data yelded the following regression Equation: rate = -3.915´10 -6 + 5.271´10 -5 c (N = 9, ± tS a = 4.279´10 -5 , ± tS b = 5.285´10 -4 at the 95 % confindence level) with a coefficient of correlation, r = 0.9999. The variance was calculated 21 by statistical treatment of the calibration data at nine concentration levels and found to be 9.796´10 -10 mg ml -1 . The low value of variance speaks for the negligible scattering of the experimental data points around the regression line.
In method B, the oxidation of lansoprazole by potassium permanganate in alkaline medium was followed spectrophotometrically by measuring the decrease in absorbance at 530 nm against the reagent blank prepared similarly but without the addition of the drug. The absorbance-time curves are shown in Fig. 5 . The difference between the absorbance obtained at 2 min and the absorbance at 4, 6, 8 and 10 min was plotted against the concentration of lansoprazole and the corresponding linear regression with the correlation coefficient is summarized in Table II The accuracy and precision of the proposed procedures (Method A and B) was established by measuring the content of lansoprazole at three different concentration levels (low, medium and high) within one day and on five consecutive days. The intra day and inter day assays were performed by performing six independent analyses at the 10.0, 60.0 and 130.0 mg ml -1 concentration levels using method A. The same assays (intra and inter day) were also performed for method B at the concentration levels: 10.0, 30.0 and 60.0 mg ml -1 on one day, as well as on five consecutive days. The results of the standard deviation, relative standard deviation and mean recoveries obtained by intra day and inter day assays for method A and B are acceptable and can be considered to be very satisfactory (Table III) . As an additional demonstration of the accuracy, recovery experiments were performed by adding a known amount of lansoprazole to pre-analysed dosage forms. The total amount of lansoprazole was determined by the proposed methods and the results are reported in Table IV . It is evident from the Table that the mean recoveries were in the range of 99.48 % -100.38 % and 99.31 % -100.18 % for methods A and B, respectively.
The proposed methods (A and B) were successfully applied to the determination of lansoprazole in capsules. The results of the proposed methods were compared to those of the reference method 15 using point and interval hypothesis tests. The calculated t-and F-values, shown in Table V , were less than the theoretical ones, 23 confirming the accuracy and precision at the 95 % confidence level. The interval hypothesis test 24 also confirmed that the true bias for all the samples was smaller than ± 2 % at the 95 % confidencel level, since the acceptable interval is within q L = 0.98 and q U = 1.02. Razijen je jednostavan kineti~ki spektrofotometrijski metod za odre|ivawe lansoprazola u farmaceutskim formulacijama. Metod se zasniva na oksidaciji leka alkalnim kalijum-permanganatom na sobnoj temperaturi. Reakcija je pra}ena spektrofotometrijski merewem porasta apsorpcije usled stvarawa MnO Statisti~ko pore}ewe rezultata predlo`enih postupaka sa referentnim spektrofotometrijskim metodama pokazalo je izvanredno slagawe i ukazalo da ne postoji zna~aj-na razlika izme|u upore|enih metoda u pogledu ta~nosti i preciznosti. Interval testa hipoteze je tako|e odre|en i odstupawe svih uzoraka je mawe od ± 2 %.
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